×
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
LON:CEL

Celadon Pharmaceuticals Share Forecast, Price & News

GBX 95
-0.50 (-0.52%)
(As of 06/29/2022 04:30 PM ET)
Add
Compare
Today's Range
95
95
50-Day Range
N/A
52-Week Range
85
160
Volume
1,000 shs
Average Volume
N/A
Market Capitalization
£58.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
30 days | 90 days | 365 days | Advanced Chart

Receive CEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celadon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CEL Stock Forecast (MarketRank)

Overall MarketRank

1.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

About Celadon Pharmaceuticals

Celadon Pharmaceuticals Plc, a pharmaceutical company, engages in the research, manufacture, and supply of cannabinoids for use in approved medicines. The company focuses on growing indoor hydroponic THC cannabis for use in medicinal products used to treat chronic pain. It also intends to conduct research into cannabinoids for use in chronic pain, as well as other conditions, such as autism and multiple sclerosis. The company was founded in 2018 and is headquartered in London, the United Kingdom.

CEL Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Drug Manufacturers-Specialty & Generic
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
GBX 35.13 per share
Book Value
GBX 79.80 per share

Miscellaneous

Free Float
N/A
Market Cap
£58.59 million
Optionable
Not Optionable
Beta
N/A














Celadon Pharmaceuticals Frequently Asked Questions

Should I buy or sell Celadon Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Celadon Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Celadon Pharmaceuticals stock.
View analyst ratings for Celadon Pharmaceuticals
or view top-rated stocks.

How has Celadon Pharmaceuticals' stock price performed in 2022?

Celadon Pharmaceuticals' stock was trading at GBX 108 at the start of the year. Since then, CEL shares have decreased by 12.0% and is now trading at GBX 95.
View the best growth stocks for 2022 here
.

Who are Celadon Pharmaceuticals' key executives?

Celadon Pharmaceuticals' management team includes the following people:
  • Mr. James Short, CEO & Director
  • Ms. Kathleen Joy Long BCOMM, CA, CFO & Director (Age 44)

What is Celadon Pharmaceuticals' stock symbol?

Celadon Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "CEL."

How do I buy shares of Celadon Pharmaceuticals?

Shares of CEL and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Celadon Pharmaceuticals' stock price today?

One share of CEL stock can currently be purchased for approximately GBX 95.

How much money does Celadon Pharmaceuticals make?

Celadon Pharmaceuticals (LON:CEL) has a market capitalization of £58.59 million.

How can I contact Celadon Pharmaceuticals?

The official website for Celadon Pharmaceuticals is www.celadonpharma.co.uk. The company can be reached via phone at 44 20 3150 0252.

This page (LON:CEL) was last updated on 6/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.